Home / Business and Economy / Novo Nordisk Slashes Wegovy Price by 37% in India
Novo Nordisk Slashes Wegovy Price by 37% in India
19 Nov
Summary
- Novo Nordisk India head announced a significant 37% price cut for Wegovy.
- The company is strategically preparing for semaglutide patent expiry next year.
- Ozempic is scheduled for launch in India within the next three months.
Novo Nordisk India has announced a significant 37% price cut for its obesity drug Wegovy, a strategic move aimed at making the medication more accessible to a wider population. Vikrant Shrotriya, the India head, revealed this decision, emphasizing that it was driven by patient needs and a long-term vision for the Indian market.
The company is proactively preparing for the upcoming expiry of the semaglutide patent next year. To navigate the anticipated increase in competition from generics, Novo Nordisk plans to leverage its established reputation for trust, quality, and consistency, alongside extensive patient education initiatives.
Furthermore, Novo Nordisk is set to launch Ozempic in India within the next three months. The final pricing for Ozempic will be determined after thorough market research to ensure competitiveness and accessibility, reflecting the company's patient-centric approach.
